Vanguard Group Inc Sorrento Therapeutics, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.74 - $1.83 $5.19 Million - $12.8 Million	7,019,380 Added 31.17%	29,535,954 $26.3 Million
Q3 2022 Nov 14, 2022	BUY	$1.51 - $2.88 $2.45 Million - $4.67 Million	1,620,150 Added 7.75%	22,516,574 $35.4 Million
Q2 2022 Aug 12, 2022	BUY	$1.24 - $2.33 $6.19 Million - $11.6 Million	4,995,039 Added 31.41%	20,896,424 $42 Million
Q1 2022 May 13, 2022	BUY	$2.0 - $4.9 $417,310 - $1.02 Million	208,655 Added 1.33%	15,901,385 $37.1 Million
Q4 2021 Feb 14, 2022	BUY	$4.65 - $7.23 $866,002 - $1.35 Million	186,237 Added 1.2%	15,692,730 $73 Million
Q3 2021 Nov 12, 2021	BUY	$7.41 - $10.99 $10.2 Million - $15.1 Million	1,376,502 Added 9.74%	15,506,493 $118 Million
Q2 2021 Aug 13, 2021	BUY	$6.35 - $10.0 $89.7 Million - $141 Million	14,129,991 New	14,129,991 $137 Million

5.47M

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.